Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer

Hepato-Gastroenterology

Volumn 59, Issue 119, 2012, Pages 2196-2201

  Doventas, Alper ^a   Bilici, Ahmet ^b   Demirelli, Fuat ^c   Ersoy, Gokhan ^c   Turna, Hande ^c   Doventas, Yasemin ^d  

^a Istanbul Education and Research Hospital   (Turkey)

^b DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

c erb B2 protein; Cd44 protein; Gastric cancer; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; GASTRECTOMY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STAINING; STOMACH CANCER; TISSUE SECTION;

EID: 84872070036     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10498     Document Type: Article

References (35)

1. Lesley I, Hyman R, Kincade PW: CD44 and its interaction with extracellular matrix. Adv Immunol 1993;54:271-335.
2. St John T, Meyer J, Idzerda R, Gallatin WM: Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 1990; 60:45-52.
3. Goodfellow PN, Banting G, Wiles MV, et al.: The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur J Immunol 1982; 12:659-663.
4. Goodison S, Urquidi V, Tarin D: CD44 cell adhesion molecules. Mol Pathol 1999; 52:189-196.
5. Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA: Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 1993; 82:3539-3547.
6. Terpe HJ, Stark H, Prehm P, Günthert U: CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. Histochemistry 1994; 101:79-89.
7. Gansauge F, Gansauge S, Zobywalski A, et al.: Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Cancer Res 1995; 55:5499-5503.
8. Lesley J, Kincade PW, Hyman R: Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody. Eur J Immunol 1993; 23:1902-1909.
9. Sleeman J, Rudy W, Hofmann M, Moll J, Herrlich P, Ponta H: Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. J Cell Biol 1996; 135:1139-1150.
10. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198:165-184.
11. Press MF, Bernstein L, Thomas PA, et al.: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15:2894-2904.
12. Xu FJ, Stack S, Boyer C, et al.: Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 1997; 3:1629-1634.
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer Statistics 2009. CA Cancer J Clin 2009; 59:225-249.
14. Desai AM, Pareek M, Nightingale PG, Fielding JW: Improving outcomes in gastric cancer over 20 years. Gastric Cancer 2004; 7:196-201.
15. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11-20.
16. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725-730.
17. Hohenberger P, Gretschel S: Gastric cancer. Lancet 2003; 362:305-315.
18. Dicken BJ, Bigam DL, Cass C, et al.: Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241:27-39.
19. Galizia G, Lieto E, Orditura M, et al.: Epidemial growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007; 31:1458-1468.
20. Kim JG, Sohn SK, Chae YS, et al.: Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 2007; 18:1030-1036.
21. Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L, Hung MC: Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 1997; 272:27913-27918.
22. Tal M, Wetzler M, Josefberg Z, et al.: Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 1988; 48:1517-1520.
23. Noguchi H, Sakamoto C, Wada K, et al.: Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells. Gastroenterology 1999; 117:1119-1127.
24. Allgayer H, Babic R, Gruetzner KU, et al.: c-erb-B2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18:2201-2209.
25. Heider KH, Dämmrich J, Skroch-Angel P, et al.: Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993; 53:4197-4203.
26. nd English ed. Gastric Cancer 1998; 1:10-24.
27. th ed. Philadelphia: Lippincott-Raven; 1997.
28. Mizutani T, Onda M, Tokunaga A, et al.: Relationship of C-erb-B2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993; 72:2083-2088.
29. Uchino S, Tsuda H, Maruyama K, et al.: Overexpression of c-erb-B2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993; 72:3179-3184.
30. Kameda T, Yasui W, Yoshida K, et al.: Expression of ERBB2 in human gastric carcinomas: Relationship between p185. Expression and the gene amplification. Cancer Res 1990; 50:8002-8009.
31. Yonemura Y, Ninomiya I, Yamaguchi A, et al.: Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51:1034-1038.
32. Yonemura Y, Ninomiya I, Ohoyama S, et al.: Correlation of c-erb-B2 protein expression and lymph node status in early gastric cancer. Oncology 1992; 49:363-367.
33. Tateishi M, Toda T, Minamisono Y, et al.: Clinicopathological significance of c-erb-B2 protein expression in human gastric carcinoma. Surg Oncol 1992; 49:209-212
34. Hilton D, West K: c-erb-B2 oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol 1992; 45:454-456.
35. Mayer B, Jauch KW, Günthert U, et al.: De-novo expression of CD44 and survival in gastric cancer. The Lancet 1993; 342:1019-1022.